(UroToday.com) As part of a plenary presentation at the virtual 2020 European Association of Urology (EAU) Annual Meeting assessing “Modern prostate cancer imaging in daily practice,” Bertrand Tombal, MD, PhD, followed Annika Herlemann, MD’s presentation by suggesting we start with early imaging for patients with biochemical recurrence following initial local therapy. His first argument was […]
(UroToday.com) As part of a plenary presentation at the European Association of Urology (EAU) Virtual Annual Meeting assessing “Modern prostate cancer imaging in daily practice,” Annika Herlemann, MD, presented the case of a patient who developed biochemical recurrence following radical prostatectomy. At the time of presentation, he was 57 years old with a family history of prostate […]
(UroToday.com) The focal therapy for prostate cancer thematic session at the virtual 2020 European Association of Urology 2020 annual meeting featured two talks on outcomes of salvage radical prostatectomy after focal therapy, with Sebastien Crouzet, MD, PhD, discussing the ability to achieve good function and pathological results after this procedure. Dr. Crouzet notes that strict […]
(UroToday.com) As part of a plenary presentation at the European Association of Urology (EAU) Virtual Annual Meeting assessing “Modern prostate cancer imaging in daily practice,” Dr. Jenster examined the role of genomics to complement imaging in patients undergoing investigation for prostate cancer.
(UroToday.com) As part of a plenary presentation at the European Association of Urology (EAU) Virtual Annual Meeting assessing “Modern prostate cancer imaging in daily practice”, Dr. Mauer followed Dr. Herlemann’s presentation by suggesting we start with metastasis directed therapy with surgery for patients with biochemical recurrence following initial local therapy.
(UroToday.com) Dr. Angelika Borkowetz concluded the midterm oncological results for focal therapy thematic session discussing the utility of VTP Tookad. VTP Tookad utilizes padeliporfin vascular-targeted photodynamic therapy to treat clinically localized prostate cancer. Inclusion criteria for VTP are as follows:
Ashish Kamat: Welcome to UroToday’s Bladder Cancer Center of Excellence. I’m Ashish Kamat, Professor of Urology at MD Anderson Cancer Center in Houston, Texas. It’s my pleasure today to welcome Dr. Renu Eapen, who is a urologist at Peter Mac Cancer Center and the Olivia Newton-John Cancer Center and Austin Health. Joining us today all […]
(UroToday.com) As part of the focal therapy for prostate cancer thematic session at the virtual EAU 2020 meeting, Hashim Ahmed from London discussed midterm oncological results of focal cryoablation therapy. Dr. Ahmed notes that we must remember the priorities for our patients, in particular the risks and benefits of treatment for localized prostate cancer. Focal […]
(UroToday.com) Focal therapy for prostate cancer was featured as a thematic session at the EAU 2020 virtual meeting, including a discussion on oncologic outcomes of high-intensity focused ultrasound (HIFU) hemi-ablation by Jonathan Olivier, MD, MSc. According to Dr. Olivier, inclusion criteria for hemi-gland ablation are as follows: Primary treatment for GG1, GG2, and low volume […]
(UroToday.com) At the Virtual 2020 European Association of Urology Annual Meeting, the focal therapy for prostate cancer thematic session featured a discussion on irreversible electroporation focal ablation by Phillip Stricker, MBBS, FACS, from Sydney, Australia. His inclusion criteria for irreversible electroporation focal ablation are typically as follows: Primary treatment: generally unilateral GG2 or favorable GG3 […]
